Research analysts covering RAD.
Recent press releases and 8-K filings for RAD.
Radiopharm Theranostics Provides Clinical Pipeline Update and 2026 Milestones
RAD
New Projects/Investments
Guidance Update
- Radiopharm Theranostics (RAD) is a clinical-stage radiotherapeutics company with five molecules in clinical development, including an imaging agent for brain metastasis (RAD101) in Phase II and four therapeutic molecules.
- The company expects 2026 to be a pivotal year, with the full Phase II data for RAD101 expected before June 2026 and significant clinical data for therapeutic programs RAD204 and RAD102 by mid-2026.
- Radiopharm Theranostics maintains a cash runway until the beginning of Q1 2027, with a quarterly burn rate of approximately $6 million-$7 million.
- The company emphasizes its first-in-class position for its PD-L1 radiopharmaceutical and its lead in HER2 and B7-H3 development against competitors.
Jan 21, 2026, 2:05 PM
Radiopharm Theranostics Provides Clinical Pipeline Update and Financial Outlook
RAD
New Projects/Investments
Guidance Update
- Radiopharm Theranostics is a clinical-stage radiotherapeutics company with five molecules in clinical development, including an imaging agent (RAD101) for brain metastasis in Phase II and four therapeutic molecules.
- The company expects to complete enrollment for its lead imaging agent, RAD101, by March or April 2026 and report full Phase II clinical data before June 2026.
- Radiopharm maintains a competitive advantage, often being first-in-class or significantly ahead of competitors in its target indications, and has a secure and redundant supply chain for isotopes.
- The current burn rate is approximately $6 million-$7 million per quarter, and the company has sufficient cash to operate until the beginning of Q1 2027.
- Potential commercialization for RAD101 is projected around 2029, with the company open to partnerships for later-stage development and commercialization.
Jan 21, 2026, 2:05 PM
Radiopharm Theranostics Provides Update on Clinical Pipeline and Financial Outlook
RAD
New Projects/Investments
Guidance Update
- Radiopharm Theranostics is a clinical-stage radiotherapeutics company with five molecules in clinical trials, including RAD101, an imaging agent for brain metastasis in Phase II, which is expected to complete enrollment around March or April 2026 and report full clinical data before June 2026.
- The company maintains a burn rate of approximately $6 million to $7 million per quarter and has sufficient cash to fund operations until the beginning of Q1 2027.
- The closest product to potential revenue generation, RAD101, is projected for market launch in 2029, following Phase III completion by the end of 2028.
- Radiopharm Theranostics highlights its first-in-class position for several molecules, including RAD101 and PD-L1 radiopharmaceuticals, and has strategic partnerships with Lantheus (15% shareholder) and MD Anderson Cancer Center.
Jan 21, 2026, 2:05 PM
Radiopharm Theranostics Reports Positive Interim Phase IIb Results for RAD-101
RAD
New Projects/Investments
Guidance Update
- Radiopharm Theranostics (RAD) announced positive interim analysis results for its RAD-101 Phase IIb study, with 11 out of 12 patients achieving the primary endpoint.
- RAD-101 is an imaging agent designed to differentiate between tumor recurrence and radiation necrosis in brain metastases following stereotactic radiosurgery.
- The Phase IIb readout is anticipated in the first half of 2026, with a Phase III study expected to enroll around 150 patients.
- The company estimates a U.S. market potential exceeding $500 million annually at peak sales for RAD-101, noting no current competition in clinical development for this indication.
- Radiopharm Theranostics is also exploring a therapeutic version of RAD-101 and advancing other pipeline programs.
Dec 15, 2025, 11:00 PM
RAD Provides Update on RAD-101 Brain Metastasis Imaging Agent Study
RAD
New Projects/Investments
Product Launch
Guidance Update
- RAD-101, an imaging agent targeting fatty acid synthase in brain metastases, is currently in a Phase IIB study in the U.S. with 30 patients. The study has shown a positive interim analysis, and the Phase IIB readout is anticipated in the first half of 2026.
- Preclinical data demonstrated superior tumor-to-brain ratio compared to 18F FTG, and Phase IIA results indicated high tracer uptake in brain metastases, with a correlation between higher SUV (greater than 2) and shorter overall survival.
- The estimated U.S. market potential for RAD-101 is $500 million annually at peak sales, driven by 300,000 new patients diagnosed with brain metastasis each year and a projected dose price of $4,800-$5,000.
- RAD-101 currently faces no competition in clinical development for brain metastasis imaging, providing a unique leadership position in the field.
Dec 15, 2025, 11:00 PM
Radiopharm Theranostics Provides Update on RAD-101 Brain Metastasis Imaging Agent Study
RAD
New Projects/Investments
Guidance Update
- Radiopharm Theranostics' RAD-101 is an imaging agent designed to target fatty acid synthase in brain metastases, with a Phase IIB study currently recruiting patients in the U.S..
- The company has reported positive interim analysis results for the Phase IIB study, with the full readout anticipated in the first half of 2026.
- RAD-101 aims to address an unmet medical need by accurately differentiating active tumor from radiation necrosis, a challenge for standard MRI, potentially enabling earlier diagnosis and treatment for patients.
- An independent economic analysis projects an addressable market of 300,000 patients annually in the U.S. for RAD-101, with potential annual peak sales exceeding $500 million at an estimated price of $4,800-$5,000 per dose.
- Radiopharm Theranostics anticipates a Phase III study involving approximately 150 patients will be necessary for regulatory approval, and currently identifies no competition in clinical development for brain metastasis imaging agents.
Dec 15, 2025, 11:00 PM
Radiopharm Theranostics Provides Update on Clinical Pipeline and Cash Runway
RAD
New Projects/Investments
Guidance Update
- Radiopharm Theranostics, dual-listed on NASDAQ with ticker RADX since December 2024, specializes in radiopharmaceutical imaging and therapies, focusing on highly differentiated mechanisms of action such as PD-L1, HER2, and B7-H3.
- The company expects to have five molecules in clinical stage by the end of 2025. Its lead imaging agent, RAD101 for brain metastasis, is in Phase IIB, with top-line results anticipated by Q1 2026 and full results by Q3 2026.
- RAD101 has an estimated market potential of over $500 million in yearly sales in the US alone, with some internal projections suggesting it could reach $500-$700 million.
- Radiopharm Theranostics maintains strategic partnerships, including a co-development agreement with Lantheus, which is also its largest shareholder with approximately 12% ownership, and a joint venture with MD Anderson Cancer Center for new radiopharmaceutical development.
- A recent capital raise in October 2025 has extended the company's cash runway into Q1 2027.
Nov 4, 2025, 5:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more